About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and
a leader in a new industry model Growth Pharma.
Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology,
gastroenterology, womens health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the
Companys R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the
pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.
Our Companys success is powered by our more than 15,000 global
colleagues commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what it is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver
innovative and meaningful treatments that help people around the world live healthier lives every day.
For more information, visit Allergans
website at www.Allergan.com.
About Vitae Pharmaceuticals
Vitae Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class product candidates with potential to transform the treatment paradigm
for patients with significant unmet medical needs. Initial indications being pursued include psoriasis, other autoimmune disorders, and atopic dermatitis. Vitaes lead clinical assets include VTP-43742, an oral RORyt inhibitor currently being
studied in patients with moderate to severe psoriasis, and VTP-38543, an LXRß selective agonist being studied in patients with mild to moderate atopic dermatitis.
For additional information, please visit Vitaes website at www.vitaepharma.com.
Allergan Cautionary Statement Regarding Forward-Looking Statements
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect
Allergans current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may
differ materially from Allergans current expectations depending upon a number of factors affecting Allergans business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions,
if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergans products; difficulties or delays in manufacturing; the ability of Allergan to complete the acquisition of Vitae; and other risks
and uncertainties detailed in Allergans periodic public filings with the Securities and Exchange Commission, including but not limited to Allergans Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report
on Form 10-Q for the quarter ended June 30, 2016 (such periodic public filings having been filed under the Actavis plc name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these